Literature DB >> 15436856

The prothrombin conversion accelerator of serum (SPCA): its partial purification and its properties compared with serum AC-globulin.

B ALEXANDER, R GOLDSTEIN, G LANDWEHR.   

Abstract

Entities:  

Keywords:  BLOOD

Mesh：

Substances：

Year:  1950        PMID： 15436856      PMCID： PMC436124          DOI： 10.1172/JCI102322

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  9 in total

1.  The fifth coagulation factor (;Factor V'). Preparation and properties.

Authors:  P A Owren
Journal:  Biochem J       Date:  1948       Impact factor: 3.857

2.  STUDIES ON THE ACTIVATION OF A SERUM "PROTHROMBIN-CONVERTING FACTOR".

Authors:  R F Jacox
Journal:  J Clin Invest       Date:  1949-05       Impact factor: 14.808

3.  HUMAN PROTHROMBIN: QUANTITATIVE STUDIES ON THE PLASMA LABILE FACTOR AND THE RESTORATIVE EFFECTS OF NORMAL, HYPOFI-BRINOGENEMIC, AND HEMOPHILIC PLASMA ON THE PROTHROMBIN OF STORED PLASMA.

Authors:  B Alexander; A De Vries; E Addelson
Journal:  J Clin Invest       Date:  1949-01       Impact factor: 14.808

4.  The Function of Ac-Globulin in Blood Clotting.

Authors:  A G Ware; R C Murphy; W H Seegers
Journal:  Science       Date:  1947-12-19       Impact factor: 47.728

5.  A Prothrombin Conversion Accelerator in Serum.

Authors:  B Alexander; A de Vries; R Goldstein; G Landwehr
Journal:  Science       Date:  1949-05-27       Impact factor: 47.728

6.  SILICONES AND BLOOD COAGULATION.

Authors:  L B Jaques; E Fidlar; E T Feldsted; A G Macdonald
Journal:  Can Med Assoc J       Date:  1946-07       Impact factor: 8.262

7.  Evolution of a prothrombin conversion accelerator in stored human plasma and prothrombin fractions.

Authors:  B ALEXANDER; G LANDWEHR
Journal:  Am J Physiol       Date:  1949-11

8.  THE COAGULATION DEFECT IN HEMOPHILIA. THE EFFECT IN HEMOPHILIA OF INTRAMUSCULAR ADMINISTRATION. OF A GLOBULIN SUBSTANCE DERIVED FROM NORMAL HUMAN PLASMA.

Authors:  F J Pohle; F H Taylor
Journal:  J Clin Invest       Date:  1937-09       Impact factor: 14.808

9.  Prothrombin consumption, serum prothrombic activity and prothrombin conversion accelerator in hemophilia and thrombocytopenia.

Authors:  B ALEXANDER; G LANDWEHR
Journal:  J Clin Invest       Date:  1949-11       Impact factor: 14.808
  9 in total
  17 in total

1.  NOMENCLATURE of blood-clotting factors.

Authors: 
Journal:  Br Med J       Date:  1959-05-16

2.  Nomenclature of blood clotting factors; acceptance by the International Committee on nomenclature of four factors, their characteristics and international number.

Authors:  I S WRIGHT
Journal:  Can Med Assoc J       Date:  1958-04-15       Impact factor: 8.262

3.  Application of continuous flow electrophoresis to the study of the blood coagulation proteins and the fibrinolytic enzyme system. I. Normal human materials.

Authors:  J H LEWIS; D WALTERS; P DIDISHEIM; W R MERCHANT
Journal:  J Clin Invest       Date:  1958-09       Impact factor: 14.808

4.  [The mechanism of formation of coagulating factors prothrombin and factor VII].

Authors:  H G LASCH; L ROKA
Journal:  Klin Wochenschr       Date:  1954-05-15

5.  [Effect of blood transfusion on coagulation factors].

Authors:  H MAURER
Journal:  Klin Wochenschr       Date:  1953-07-01

6.  Partial purification of human prothrombin and proconvertin: their characteristics and interaction.

Authors:  J H LEWIS; J H FERGUSON
Journal:  J Clin Invest       Date:  1953-10       Impact factor: 14.808

7.  Identification of a thromboplastin inhibitor in serum and in plasma.

Authors:  G F LANCHANTIN; A G WARE
Journal:  J Clin Invest       Date:  1953-04       Impact factor: 14.808

8.  Clinical implications of plasma fractionation.

Authors:  I H SCHEINBERG
Journal:  Bull N Y Acad Med       Date:  1954-10

9.  On the comparative prothrombic activity of human and dog blood.

Authors:  A J QUICK; C V HUSSEY
Journal:  J Clin Invest       Date:  1951-09       Impact factor: 14.808

10.  The labile factor of prothrombin conversion: its consumption under normal and pathological conditions affecting blood coagulation.

Authors:  B ALEXANDER; R GOLDSTEIN; G LANDWEHR
Journal:  J Clin Invest       Date:  1951-03       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.